'Serial Killer’ CAR-T Could Help Autolus Bounce Back
After A Hard Year, The UK Biotech Looks For ASH Data Upturn
Data presentations at next week’s ASH meeting will be vital for Autolus to restore confidence in pipeline.
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data